BioNTech co-founder Ugur Sahin said on Thursday the frontrunner Covid-19 vaccine his German firm is developing with Pfizer could be rolled out before the year is over in the United States or Europe.
Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...
BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is ...
In January last year, German biotech company BioNTech acquired African AI startup InstaDeep for over $550 million, a deal finalized in July of the same year. InstaDeep, whose exit is currently the ...
JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (BNTX) (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech (NTGN), visited Israel to meet with ...
BioNTech said Thursday it has agreed to acquire smaller biotech CureVac in a $1.25 billion all-stock deal in a push to advance its cancer drug portfolio. CureVac stock soared 31% to $5.33 in premarket ...
The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values CureVac at around $1.25 billion. Once complete, CureVac will be wholly absorbed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results